Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.11
CRL's Cash-to-Debt is ranked lower than
90% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.33 vs. CRL: 0.11 )
Ranked among companies with meaningful Cash-to-Debt only.
CRL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: 0.3 Max: N/A
Current: 0.11
Equity-to-Asset 0.33
CRL's Equity-to-Asset is ranked lower than
83% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. CRL: 0.33 )
Ranked among companies with meaningful Equity-to-Asset only.
CRL' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.28  Med: 0.49 Max: 0.72
Current: 0.33
-0.28
0.72
Interest Coverage 8.38
CRL's Interest Coverage is ranked lower than
69% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.14 vs. CRL: 8.38 )
Ranked among companies with meaningful Interest Coverage only.
CRL' s Interest Coverage Range Over the Past 10 Years
Min: 4.09  Med: 8.2 Max: 14.87
Current: 8.38
4.09
14.87
Piotroski F-Score: 4
Altman Z-Score: 2.83
Beneish M-Score: -2.41
WACC vs ROIC
6.98%
9.06%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 14.41
CRL's Operating Margin % is ranked higher than
80% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. CRL: 14.41 )
Ranked among companies with meaningful Operating Margin % only.
CRL' s Operating Margin % Range Over the Past 10 Years
Min: -33.48  Med: 14.3 Max: 18.46
Current: 14.41
-33.48
18.46
Net Margin % 9.28
CRL's Net Margin % is ranked higher than
78% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.44 vs. CRL: 9.28 )
Ranked among companies with meaningful Net Margin % only.
CRL' s Net Margin % Range Over the Past 10 Years
Min: -38.84  Med: 9.4 Max: 12.55
Current: 9.28
-38.84
12.55
ROE % 19.61
CRL's ROE % is ranked higher than
87% of the 213 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.56 vs. CRL: 19.61 )
Ranked among companies with meaningful ROE % only.
CRL' s ROE % Range Over the Past 10 Years
Min: -34.11  Med: 16.92 Max: 21.25
Current: 19.61
-34.11
21.25
ROA % 6.34
CRL's ROA % is ranked higher than
76% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.39 vs. CRL: 6.34 )
Ranked among companies with meaningful ROA % only.
CRL' s ROA % Range Over the Past 10 Years
Min: -21.02  Med: 6.29 Max: 7.58
Current: 6.34
-21.02
7.58
ROC (Joel Greenblatt) % 30.89
CRL's ROC (Joel Greenblatt) % is ranked higher than
74% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.92 vs. CRL: 30.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CRL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -50.32  Med: 19.05 Max: 32.31
Current: 30.89
-50.32
32.31
3-Year Revenue Growth Rate 13.40
CRL's 3-Year Revenue Growth Rate is ranked higher than
73% of the 159 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. CRL: 13.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CRL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -17.6  Med: 7 Max: 13.4
Current: 13.4
-17.6
13.4
3-Year EBITDA Growth Rate 14.20
CRL's 3-Year EBITDA Growth Rate is ranked higher than
67% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.60 vs. CRL: 14.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CRL' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -18.2  Med: 8.15 Max: 25.2
Current: 14.2
-18.2
25.2
3-Year EPS without NRI Growth Rate 14.40
CRL's 3-Year EPS without NRI Growth Rate is ranked higher than
66% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.00 vs. CRL: 14.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CRL' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -29.4  Med: 9.35 Max: 43.3
Current: 14.4
-29.4
43.3
GuruFocus has detected 5 Warning Signs with Charles River Laboratories International Inc $CRL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CRL's 30-Y Financials

Financials (Next Earnings Date: 2017-08-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 541711    SIC: 8732
Compare:NAS:BRKR, OTCPK:CZMWY, NAS:PRAH, NAS:PRXL, NYSE:ALR, NAS:ICLR, NAS:VWR, OTCPK:SWTUY, OTCPK:DSRLF, NAS:EXAS, NAS:CPHD, NYSE:BIO, NAS:DXCM, NAS:INCR, NAS:NEOG, OTCPK:MRCHF, NYSE:PKI, NAS:MYGN, NAS:AXDX, NAS:QGEN » details
Traded in other countries:RV6.Germany,
Headquarter Location:USA
Charles River Laboratories International Inc provides research models and services required to enable in vivo drug discovery and development.

Charles River Laboratories is a leading provider of drug discovery and development services. With roughly 50% of market share worldwide, the research model and services segment is the leading provider of animal models for laboratory testing. The remainder of Charles River's revenue comes from its preclinical services segment, which offers discovery, toxicology, pathology, and its manufacturing testing services to pharmaceutical, biotechnology, and device companies.

Guru Investment Theses on Charles River Laboratories International Inc

John Rogers Comments on Charles River Laboratories Intl - Jan 20, 2017

Other holdings underperformed. Scientific research firm Charles River Laboratories Intl, Inc. (NYSE:CRL) slid –8.58% due to contracting customer spending and a general downturn in health care stocks. Like other similar firms, Charles River expanded over the last 15 years to be able to handle peak medical research, but as drug companies scaled back, there was clearly overcapacity. The company’s drug discovery business is still a bit slack. That said, many health care stocks slid this quarter during a huge rotation to financials. We think the current issues are largely cyclical but the secular push toward solving medical problems through pharmaceuticals remains intact—a long-term tailwind for Charles River.



From John Rogers (Trades, Portfolio)' Ariel Fund fourth quarter 2016 commentary.



Check out John Rogers latest stock trades

Top Ranked Articles about Charles River Laboratories International Inc

John Rogers Buys Cardinal Health, Mattel, Nielsen Guru's largest 1st-quarter buys
John Rogers (Trades, Portfolio) is the founder of Ariel Investment LLC, which he started in 1983. He manages a portfolio composed of 188 stocks with a total value of $8.505 billion. During the first quarter the guru bought shares in the following stocks: Read more...
John Rogers Comments on Charles River Laboratories Intl Guru stock highlight
Other holdings underperformed. Scientific research firm Charles River Laboratories Intl, Inc. (NYSE:CRL) slid –8.58% due to contracting customer spending and a general downturn in health care stocks. Like other similar firms, Charles River expanded over the last 15 years to be able to handle peak medical research, but as drug companies scaled back, there was clearly overcapacity. The company’s drug discovery business is still a bit slack. That said, many health care stocks slid this quarter during a huge rotation to financials. We think the current issues are largely cyclical but the secular push toward solving medical problems through pharmaceuticals remains intact—a long-term tailwind for Charles River. Read more...
Carl Data Solutions Announces Closing of Initial Tranche of $2,000,000 Growth Financing Agreement With AIP Asset Management

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jun 30, 2016) - Further to its press release dated April 25, 2016, Carl Data Solutions Inc. (CSE:CRL)(FRANKFURT:7C5) ("Carl" or the "Company"), a developer of Big-Data-as-a-Service ("BDaaS") and Internet-of-Things ("IoT") solutions for data collection and analysis, is pleased to announce that it has executed a Note Purchase Agreement (the "Agreement") with AIP Asset Management Inc. ("AIP") pursuant to which Carl has agreed to issue certain funds of AIP (collectively, the "Holders") senior secured collateralized convertible notes (the "Notes") in the aggregate principal amount of CAD $2,000,000 (the "Offering"). The Company has received in escrow gross proceeds of $2,000,000. In connection with the closing of the first tranche of the Offering, the Company has issued Notes in the aggregate principal amount of $500,000 (the "Initial Notes"). Notes representing the balance of the $2,000,000 (the "Additional Notes") will be issued upon satisfaction of the various closing conditions as set out in the Agreement. The Notes are due and payable two years from their respective date of issue, and will bear an interest rate of 10% per annum calculated and payable monthly, in advance. At the option of the Holders, the Notes will be convertible into common shares of the Company (each, a "Share") at a conversion price of $0.45 per Share, subject to adjustment as provided in the Agreement. If, at any time following four months after the issue date of any Note, the closing price per Share is at least $0.75 per Share for 30 consecutive days with a daily weighted average trading volume of more than 400,000 Shares, the Company may force the conversion of one half of the aggregate principal amount of the outstanding Notes (the "Initial Conversion"). After the first anniversary of the issuance of the Notes, the Company, at its option, may prepay, without notice or penalty, the principal amount of all of the outstanding Notes in full or in part, together with any accrued and unpaid interest. In connection with the issuance of the Initial Notes, the Company issued 400,000 bonus Shares to the purchasers of the Initial Notes. The Company has paid AIP a $100,000 closing fee concurrently with the issuance of the Initial Notes and certain other consideration as provided in the Agreement, a copy of which will be filed on SEDAR. Proceeds from the Notes will be used for the development of the Company's BDaaS technology, for further development of the FlowWorks application, sales and marketing, and for general working capital purposes. Greg Johnston, CEO of Carl, commented, "We're very pleased to have entered into the Agreement and closed the first tranche of the Offering with AIP. It is great to have the confidence of a long-term strategic investor that has expressed an intention to support Carl as we grow. The additional capital will allow Carl to accelerate our business plan by way of acquisitions, the launch of new applications, and expansion of our BDaaS and IoT technology." All securities issued or issuable in connection with the Offering are or will be subject to a statutory hold period expiring on the date that is four months and one day after the distribution date. None of the securities issued or issuable in connection with the Offering will be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. About AIP Asset Management Inc. AIP Asset Management Inc. ("AIP") is a Toronto based privately held investment firm as - Investment Fund Manager, Portfolio Manager and Exempt Market Dealer. AIP has gained a reputation for its innovative approach to portfolio construction and commitment to investor advocacy. AIP was recently nominated for the Ernst & Young Entrepreneur of the Year Award. AIP has also been named Best Emerging Market Focused Private Investment Firm in North American at the Alternative Investment Awards and was named Best Macro Hedge Fund in Canada at the Hedge Fund Awards sponsored by Barclay Hedge. More information can be found at www.aipassetmanagement.com. About Carl Data Solutions Inc. Carl Data Solutions Inc. is focused on providing next generation information collection, storage and analytics solutions for data centric companies. Building on its recent acquisitions, FlowWorks Inc., a company that helps its clients analyze and understand all forms of environmental data through a powerful platform of data collection, monitoring, analysis, and reporting tools, and Extend to Social Media Inc., a company with an application that allows clients to leverage their customers' social networks for referral marketing and analytics, Carl develops applications to work with new cloud-based mass storage services and analytics applications (Big-Data-as-a-Service (BDaaS)). Carl is creating a virtually unlimited data storage environment from which informative visual representation of data can be created and new insights generated. Carl's goal is to deliver a comprehensive data management solution for datasets of any size and type from any source. More information can be found at www.CarlSolutions.com. On behalf of the Board of Directors: Greg Johnston, President, Chief Executive Officer, Director
Carl Data Solutions Inc. The Canadian Securities Exchange (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release. Disclaimer for Forward-Looking Information Certain statements in this press release related to the Notes and the various loans are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as "may", "should", "will", "could", "intend", "estimate", "plan", "anticipate", "expect", "believe" or "continue", or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the private placement financing of the Notes, including the proceeds to be raised pursuant to the Note financing, resale restrictions relating to the securities to be issued, and the use of proceeds to be raised pursuant to the Notes and the previously announced equity private placement; a statement that the Note financing will allow the Company to accelerate the development and launch of new applications in data intensive industries; and a statement that Carl's goal is to deliver a comprehensive data management solution for datasets of any size and type from any source. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the Company's ability to complete the private placement financing for the Notes, including the risk that the entire amount may not be raised as expected or at all, that the proceeds from the Notes may be used other than as set out in this news release and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.





Tiffany Tolmie
Corporate Communications
Carl Data Solutions Inc.
(778) 379-0275
[email protected]




Read more...

Ratios

vs
industry
vs
history
PE Ratio 29.57
CRL's PE Ratio is ranked higher than
63% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.54 vs. CRL: 29.57 )
Ranked among companies with meaningful PE Ratio only.
CRL' s PE Ratio Range Over the Past 10 Years
Min: 8.58  Med: 24.72 Max: 95.66
Current: 29.57
8.58
95.66
Forward PE Ratio 19.76
CRL's Forward PE Ratio is ranked higher than
78% of the 36 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.57 vs. CRL: 19.76 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 29.67
CRL's PE Ratio without NRI is ranked higher than
62% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.74 vs. CRL: 29.67 )
Ranked among companies with meaningful PE Ratio without NRI only.
CRL' s PE Ratio without NRI Range Over the Past 10 Years
Min: 8.51  Med: 24.33 Max: 77.86
Current: 29.67
8.51
77.86
Price-to-Owner-Earnings 23.65
CRL's Price-to-Owner-Earnings is ranked higher than
66% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 32.56 vs. CRL: 23.65 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CRL' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.56  Med: 22.89 Max: 323.25
Current: 23.65
10.56
323.25
PB Ratio 5.53
CRL's PB Ratio is ranked lower than
66% of the 210 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.94 vs. CRL: 5.53 )
Ranked among companies with meaningful PB Ratio only.
CRL' s PB Ratio Range Over the Past 10 Years
Min: 0.75  Med: 3.11 Max: 6.01
Current: 5.53
0.75
6.01
PS Ratio 2.73
CRL's PS Ratio is ranked higher than
64% of the 213 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.68 vs. CRL: 2.73 )
Ranked among companies with meaningful PS Ratio only.
CRL' s PS Ratio Range Over the Past 10 Years
Min: 1.12  Med: 2.23 Max: 3.83
Current: 2.73
1.12
3.83
Price-to-Free-Cash-Flow 21.59
CRL's Price-to-Free-Cash-Flow is ranked higher than
61% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.07 vs. CRL: 21.59 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CRL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.49  Med: 16.72 Max: 1041.48
Current: 21.59
8.49
1041.48
Price-to-Operating-Cash-Flow 16.89
CRL's Price-to-Operating-Cash-Flow is ranked higher than
64% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.63 vs. CRL: 16.89 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CRL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.82  Med: 12.43 Max: 19.72
Current: 16.89
4.82
19.72
EV-to-EBIT 21.03
CRL's EV-to-EBIT is ranked higher than
63% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. CRL: 21.03 )
Ranked among companies with meaningful EV-to-EBIT only.
CRL' s EV-to-EBIT Range Over the Past 10 Years
Min: -10.7  Med: 17.7 Max: 27.8
Current: 21.03
-10.7
27.8
EV-to-EBITDA 14.19
CRL's EV-to-EBITDA is ranked higher than
67% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.45 vs. CRL: 14.19 )
Ranked among companies with meaningful EV-to-EBITDA only.
CRL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.5  Med: 11.95 Max: 16.8
Current: 14.19
-16.5
16.8
PEG Ratio 3.23
CRL's PEG Ratio is ranked lower than
51% of the 49 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.17 vs. CRL: 3.23 )
Ranked among companies with meaningful PEG Ratio only.
CRL' s PEG Ratio Range Over the Past 10 Years
Min: 1.01  Med: 2.59 Max: 3.23
Current: 3.23
1.01
3.23
Shiller PE Ratio 179.85
CRL's Shiller PE Ratio is ranked lower than
100% of the 31 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 47.43 vs. CRL: 179.85 )
Ranked among companies with meaningful Shiller PE Ratio only.
CRL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 90.11  Med: 159.89 Max: 1940.5
Current: 179.85
90.11
1940.5
Current Ratio 1.83
CRL's Current Ratio is ranked lower than
64% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.73 vs. CRL: 1.83 )
Ranked among companies with meaningful Current Ratio only.
CRL' s Current Ratio Range Over the Past 10 Years
Min: 1.21  Med: 2.01 Max: 3.49
Current: 1.83
1.21
3.49
Quick Ratio 1.57
CRL's Quick Ratio is ranked lower than
63% of the 235 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. CRL: 1.57 )
Ranked among companies with meaningful Quick Ratio only.
CRL' s Quick Ratio Range Over the Past 10 Years
Min: 0.95  Med: 1.67 Max: 3.02
Current: 1.57
0.95
3.02
Days Inventory 32.60
CRL's Days Inventory is ranked higher than
69% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 82.10 vs. CRL: 32.60 )
Ranked among companies with meaningful Days Inventory only.
CRL' s Days Inventory Range Over the Past 10 Years
Min: 32.6  Med: 41.32 Max: 49.49
Current: 32.6
32.6
49.49
Days Sales Outstanding 62.04
CRL's Days Sales Outstanding is ranked lower than
52% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.30 vs. CRL: 62.04 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.42  Med: 59.61 Max: 65.6
Current: 62.04
53.42
65.6
Days Payable 20.33
CRL's Days Payable is ranked lower than
85% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.24 vs. CRL: 20.33 )
Ranked among companies with meaningful Days Payable only.
CRL' s Days Payable Range Over the Past 10 Years
Min: 14.93  Med: 15.77 Max: 24.16
Current: 20.33
14.93
24.16

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.10
CRL's 3-Year Average Share Buyback Ratio is ranked higher than
87% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. CRL: 0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CRL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -62.6  Med: 0.3 Max: 10.3
Current: 0.1
-62.6
10.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.51
CRL's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
75% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. CRL: 1.51 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CRL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.94  Med: 1.33 Max: 1.78
Current: 1.51
0.94
1.78
Price-to-Median-PS-Value 1.24
CRL's Price-to-Median-PS-Value is ranked lower than
64% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. CRL: 1.24 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CRL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.55  Med: 1.17 Max: 1.85
Current: 1.24
0.55
1.85
Price-to-Peter-Lynch-Fair-Value 2.98
CRL's Price-to-Peter-Lynch-Fair-Value is ranked lower than
60% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.51 vs. CRL: 2.98 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CRL' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.25  Med: 2.4 Max: 2.99
Current: 2.98
1.25
2.99
Earnings Yield (Greenblatt) % 4.74
CRL's Earnings Yield (Greenblatt) % is ranked higher than
82% of the 238 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.52 vs. CRL: 4.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CRL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -24.3  Med: 5.2 Max: 14.1
Current: 4.74
-24.3
14.1
Forward Rate of Return (Yacktman) % 13.97
CRL's Forward Rate of Return (Yacktman) % is ranked higher than
69% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.56 vs. CRL: 13.97 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CRL' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 2.8  Med: 5.6 Max: 20
Current: 13.97
2.8
20

More Statistics

Revenue (TTM) (Mil) $1,772.33
EPS (TTM) $ 3.42
Beta0.99
Short Percentage of Float3.28%
52-Week Range $67.20 - 101.27
Shares Outstanding (Mil)47.64

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,831 1,960 2,107
EPS ($) 5.02 5.52 5.96
EPS without NRI ($) 5.02 5.52 5.96
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.02%
Dividends per Share ($)
» More Articles for CRL

Headlines

Articles On GuruFocus.com
Some More Timeless Advice From the Intelligent Investor Jun 28 2017 
Seth Klarman: Value Investing in the Tech Bubble Jun 28 2017 
Pandora CEO, 2 Other Officers Resign Jun 28 2017 
Patterson-UTI Energy Is Interesting Post-Correction Jun 28 2017 
Correction Is an Opportunity to Accumulate Dorian LPG Jun 28 2017 
Charlie Tian's Interview on The Next Level Show Jun 28 2017 
Foot Locker Is the Hidden Gem of Retail Jun 28 2017 
Seeking Value in the Grocery Aisle Jun 28 2017 
Seeking Value in Bermuda: Everest Re Group Jun 28 2017 
Paulson Dives Deeper Into Valeant With Increased Holding Jun 27 2017 

More From Other Websites
Charles River Laboratories to Present at Jefferies Global Healthcare Conference Jun 05 2017
Cramer's lightning round: I'm blessing this chipmaker for a quick trade Jun 02 2017
ETFs with exposure to Charles River Laboratories International, Inc. : June 1, 2017 Jun 01 2017
Post Earnings Coverage as Charles River Laboratories' Revenue Surged 25.6%, non-GAAP EPS Jumped 32% May 30 2017
Charles River Labs Re-Enters Buy Zone; Gets Stock Rating Upgrade May 25 2017
Opening Bell, May 23, 2017 May 23 2017
Today's Bell Ringer, May 23, 2017 May 23 2017
Edited Transcript of CRL earnings conference call or presentation 10-May-17 12:30pm GMT May 16 2017
ETFs with exposure to Charles River Laboratories International, Inc. : May 16, 2017 May 16 2017
Charles River Laboratories Announces Updates to Oncology Business May 16 2017
Charles River Laboratories International, Inc. :CRL-US: Earnings Analysis: Q1, 2017 By the Numbers :... May 15 2017
​Charles River shareholders reject PETA proposal on monkey research May 12 2017
Charles River Laboratories International, Inc. breached its 50 day moving average in a Bearish... May 12 2017
Charles River beats Street 1Q forecasts May 10 2017
Charles River Laboratories Announces First-Quarter 2017 Results from Continuing Operations May 10 2017
Medical Services Stock Q1 Earnings on May 10: CRL, XON, INCR May 09 2017
4 Medical Stocks That Could Be Big Winners Next Week May 05 2017
Charles River Laboratories International, Inc. breached its 50 day moving average in a Bearish... Apr 26 2017
Charles River Laboratories Schedules First-Quarter 2017 Earnings Release and Conference Call Apr 12 2017
Charles River Laboratories International, Inc. – Value Analysis (NYSE:CRL) : April 12, 2017 Apr 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}